Akoustis Technologies, Inc. Stock

Stocks

09-09	Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT	MT
08-19	Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says	MT
08-19	Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target	MT
08-19	BMO Capital Initiates Akoustis Technologies at Outperform	MT
08-13	Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q2 Revenue $3.4M, vs. FactSet Est of $2.1M	MT
07-10	Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing	MT
07-10	Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing	MT
06-16	Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target	MT
05-22	Top Premarket Gainers	MT
05-11	Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M	MT
04-29	William Blair Initiates Aktis Oncology at Outperform	MT
03-30	Aktis Oncology Receives US FDA Approval for AKY-2519 Investigational New Drug Applications	MT
03-09	HC Wainwright Initiates Aktis Oncology at Buy With $30 Price Target	MT

09-09	Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT	MT
08-19	Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says	MT
08-19	Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target	MT
08-19	BMO Capital Initiates Akoustis Technologies at Outperform	MT
06-16	Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target	MT

24-12-16	Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process	GL
24-12-16	Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process	BU
24-12-02	Akoustis Technologies : Material Event Form 8 K	PU
24-11-15	Akoustis: Fiscal Q1 Earnings Snapshot	AQ
24-10-28	Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG	AQ

Manager	Title	Age	Since
Robert Dry COO	Chief Operating Officer	-	-
Mary Winters COO	Chief Operating Officer	-	-
Colin Hunt SAM	Sales & Marketing	-	2020-06-01

Director	Title	Age	Since
Jerry Neal CHM	Chairman	82	2016-03-13
Arthur Geiss CHM	Chairman	73	2016-03-13
Jill Frizzley BRD	Director/Board Member	50	2024-08-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/8/24	Kamran Cheema	Other	Chief Executive Officer	228,011	0.2089%
1/29/24	David Aichele	Buy	Executive/Senior Manager	80,000	0.1104%
1/29/24	Kenneth Boller	Buy	Chief Financial Officer	60,000	0.0828%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUSTIS TECHNOLOGIES, INC.	-.--%	-.--%	-	-	155
INVESTOR AB	+0.36%	+1.80%	+32.52%	+109.05%	130B
INDUSTRIVÄRDEN AB	+0.19%	+0.97%	+30.78%	+84.27%	22.5B
HAL TRUST	-0.36%	+2.07%	+22.13%	+59.20%	16.95B
MERITZ FINANCIAL GROUP INC.	-1.76%	-4.87%	+7.89%	+147.48%	14.92B
LUNDBERG B	-0.04%	+1.22%	+13.17%	+29.32%	14.48B
INVESTMENT AB LATOUR	+0.53%	+4.03%	-11.70%	+14.42%	13.87B
BAJAJ HOLDINGS & INVESTMENT LIMITED	-3.54%	-4.48%	-18.25%	+53.61%	12.69B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	-1.40%	-2.04%	+18.05%	+33.79%	12.2B
KINGDOM HOLDING COMPANY	0.00%	-5.12%	+53.77%	+72.25%	11.89B
Average	-0.61%	-0.30%	+16.48%	+67.04%	27.69B
Weighted average by Cap.	-0.21%	+1.13%	+24.32%	+87.56%